Physician profile
Michael Flamm
NPI 1225416241
$5,112.39
in general payments reported to CMS, 2019-2025
12 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,990 · 2020: $1,234 · 2021: $124 · 2022: $23.16 · 2023: $162 · 2024: $165 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,999.96 | 2019-2025 | General - Pain Management |
| Abbott Laboratories | $1,043.37 | 2019 | |
| Medtronic USA, INC. | $862.92 | 2019-2020 | |
| Nevro Corp. | $328.83 | 2019 | |
| Lilly USA, LLC | $219.16 | 2019 | |
| Mml US, INC. | $188.40 | 2025 | Reactiv8 |
| Spr Therapeutics, INC | $144.48 | 2024 | Sprint Pns System |
| Stratus Medical, LLC | $133.79 | 2023 | Nimbus |
| Abbvie INC. | $72.66 | 2022-2024 | |
| Convatec INC. | $63.07 | 2025 | |
| Allergan, INC. | $34.89 | 2020 | |
| Relievant Medsystems, INC. | $20.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.